Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)
Through the collaboration, Exonate will work with Janssen Research & Development, LLC scientiststo develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.
- Through the collaboration, Exonate will work with Janssen Research & Development, LLC scientiststo develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.
- Exonate has developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing.
- Commenting on the announcement, Dr. Catherine Beech CEO of Exonate, said: "I am absolutely delighted to enter this strategic collaboration with Janssen, we are looking forward to successfully developing a novel treatment for retinal neovascular diseases."
- Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months.